| 1. |
Myslík Manethová K. Central serous chorioretinopathy. A review[J]. Cesk Slov Oftalmol, 2024, 80(2): 59-75. DOI: 10.31348/2023/27.
|
| 2. |
Bousquet E, Provost J, Torres-Villaros H, et al. Central serous chorioretinopathy: a review[J]. J Fr Ophtalmol, 2023, 46(7): 791-802. DOI: 10.1016/j.jfo.2023.02.003.
|
| 3. |
Varghese J, Kesharwani D, Parashar S, et al. A review of central serous chorioretinopathy: clinical presentation and management[J/OL]. Cureus, 2022, 14(8): e27965[2022-08-13]. https://pubmed.ncbi.nlm.nih.gov/36120212/. DOI: 10.7759/cureus.27965.
|
| 4. |
Sahoo NK, Ong J, Selvam A, et al. Longitudinal follow-up and outcome analysis in central serous chorioretinopathy[J]. Eye (Lond), 2023, 37(4): 732-738. DOI: 10.1038/s41433-022-02044-z.
|
| 5. |
van Rijssen TJ, van Dijk E, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline[J/OL]. Prog Retin Eye Res, 2019, 73: 100770[2019-07-15]. https://linkinghub.elsevier.com/retrieve/pii/S1350-9462(18)30094-6. DOI:10.1016/j.preteyeres.2019.07.003.
|
| 6. |
Pujari A, Saluja G, Chawla R, et al. Optical coherence tomography angiography in amblyopia: a critical update on current understandings and future perspectives[J]. Eur J Ophthalmol, 2022, 32(3): 1324-1332. DOI: 10.1177/11206721211042554.
|
| 7. |
Guo J, Tang W, Xu S, et al. OCTA evaluation of treatment-naive flat irregular PED (FIPED)-associated CNV in chronic central serous chorioretinopathy before and after half-dose PDT[J]. Eye (Lond), 2021, 35(10): 2871-2878. DOI: 10.1038/s41433-020-01345-5.
|
| 8. |
陳君, 賈晨, 于旭輝. OCTA與FFA對中心性漿液性脈絡膜視網膜病變并發脈絡膜新生血管診斷價值的Meta分析[J]. 中華實驗眼科雜志, 2022, 40(7): 639-644. DOI: 10.3760/cma.j.cn115989-20200714-00494.Chen J, Jia C, Yu XH. Diagnostic value of OCTA and FFA in central serous chorioretinopathy complicated with choroidal neovascularization: a meta-analysis[J]. Chin J Exp Ophthalmol, 2022, 40(7): 639-644. DOI: 10.3760/cma.j.cn115989-20200714-00494.
|
| 9. |
Meng Y, Xu Y, Li L, et al. Wide-field OCT-angiography assessment of choroidal thickness and choriocapillaris in eyes with central serous chorioretinopathy[J/OL]. Front Physiol, 2022, 13: 1008038[2022-10-22]. https://europepmc.org/article/MED/36338482. DOI:10.3389/fphys.2022.1008038.
|
| 10. |
Podkowinski D, Foessl B, de Sisternes L, et al. Early alterations in retinal microvasculature on swept-source optical coherence tomography angiography in acute central serous chorioretinopathy[J]. Sci Rep, 2021, 11(1): 3129. DOI: 10.1038/s41598-021-82650-1.
|
| 11. |
Faghihi H, Mahmoudi A, Pour EK, et al. Choroidal features in flat irregular pigment epithelial detachment associated with chronic central serous chorioretinopathy: avascular versus vascularized[J/OL]. PLoS One, 2021, 16(9): e257763[2021-09-23]. https://pubmed.ncbi.nlm.nih.gov/34555122/. DOI: 10.1371/journal.pone.0257763.
|
| 12. |
Liu T, Lin W, Zhou S, et al. Optical coherence tomography angiography of flat irregular pigment epithelial detachments in central serous chorioretinopathy[J]. Br J Ophthalmol, 2021, 105(2): 233-238. DOI: 10.1136/bjophthalmol-2019-315318.
|
| 13. |
Mao J, Zhang C, Zhang S, et al. Predictors of anti-VEGF efficacy in chronic central serous chorioretinopathy based on intraocular cytokine levels and pigment epithelium detachment subtypes[J/OL]. Acta Ophthalmol, 2022, 100(7): e1385-e1394[2022-02-04]. https://pubmed.ncbi.nlm.nih.gov/35122421/. DOI: 10.1111/aos.15109.
|
| 14. |
Su Y, Zhang X, Gan Y, et al. Characteristics and associated factors of flat irregular pigment epithelial detachment with choroidal neovascularization in chronic central serous chorioretinopathy[J/OL]. Front Med (Lausanne), 2021, 8: 687023[2021-09-06]. https://pubmed.ncbi.nlm.nih.gov/34552940/. DOI: 10.3389/fmed.2021.687023.
|
| 15. |
Kleefeldt N, Kuehnel S, Reiser L, et al. Morphological and functional changes of secondary macular neovascularization in central serous chorioretinopathy under anti-VEGF treatment[J]. Ophthalmologie, 2025, 122(6): 442-452. DOI: 10.1007/s00347-025-02221-x.
|
| 16. |
Xu A, Lai Q, Sun G, et al. Choroidal blood flow changes in central serous chorioretinopathy[J/OL]. Sci Rep, 2025, 15(1): 9907[2025-03-22]. https://pubmed.ncbi.nlm.nih.gov/40121247/. DOI: 10.1038/s41598-025-94096-w.
|
| 17. |
You EL, Hébert M, Jin TS, et al. Comparing interventions for chronic central serous chorioretinopathy: a network meta-analysis[J]. Surv Ophthalmol, 2023, 68(4): 601-614. DOI: 10.1016/j.survophthal.2023.03.001.
|
| 18. |
Wang J, Wang Z, Liu J, et al. Chrysin alleviates DNA damage to improve disturbed immune homeostasis and pro-angiogenic environment in laser-induced choroidal neovascularization[J/OL]. Biochim Biophys Acta Mol Cell Res, 2024, 1871(3): 119657[2024-01-02]. https://pubmed.ncbi.nlm.nih.gov/38176443/. DOI: 10.1016/j.bbamcr.2023.119657.
|
| 19. |
Singh SR, Iovino C, Zur D, et al. Central serous chorioretinopathy imaging biomarkers[J]. Br J Ophthalmol, 2022, 106(4): 553-558. DOI: 10.1136/bjophthalmol-2020-317422.
|
| 20. |
Sevik MO, Aykut A, ?am F, et al. Choroidal vascularity index as an activity criterion and a treatment response measure in chronic central serous chorioretinopathy[J]. Ophthalmic Physiol Opt, 2023, 43(5): 1203-1210. DOI: 10.1111/opo.13187.
|
| 21. |
Molins B, Rodriguez A, Llorenc V, et al. Biomaterial engineering strategies for modeling the Bruch's membrane in age-related macular degeneration[J]. Neural Regen Res, 2024, 19(12): 2626-2636. DOI: 10.4103/NRR.NRR-D-23-01789.
|
| 22. |
Yu J, Jiang C, Xu G. Study of subretinal exudation and consequent changes in acute central serous chorioretinopathy by optical coherence tomography[J]. Am J Ophthalmol, 2014, 158(4): 752-756. DOI: 10.1016/j.ajo.2014.06.015.
|
| 23. |
Dubey SK, Dubey R, Jung K, et al. Deciphering age-related transcriptomic changes in the mouse retinal pigment epithelium[J]. Aging (Albany NY), 2025, 17(3): 657-684. DOI: 10.18632/aging.206219.
|